Antiretroviral Therapy Crucial in Preventing non-Hodgkin Lymphoma, YSPH Study Reinforces
A research team led by the Yale School of Public Health has found that for people living with HIV/AIDS, both recent immunosuppression and prolonged HIV viremia play important and independent roles in the development of non-Hodgkin lymphoma.
Study reveals new way to ‘rewire’ immune cells to slow tumor growth
Inside a tumor, immune cells and cancer cells battle for survival. The advantage may go to the cells that metabolize the most glucose, say Yale researchers who have identified a new way to boost immune response by metabolically “rewiring” immune cells.
Targeting a Deadly Type of Uterine Cancer
Endometrial cancer, which originates in the lining of the uterus and is the most common type of gynecological cancer, often has a good prognosis. Patients with the more frequently diagnosed type I are often cured. Type II, however, is responsible for most of the recurrences and deaths that occur in endometrial cancer. Uterine Serous Carcinoma (USC), the most aggressive kind of type II endometrial cancer, accounts for just 10 percent of endometrial tumors and is particularly deadly: in its earliest stages the survival rate can be as low as 50 percent, and for those with more advanced disease, there is no cure.
$7.5 Million Grant to Yale Researchers for Role of Viruses in Cancer
The National Cancer Institute recently awarded a five-year, $7.5 million program project grant to investigators at the Yale School of Medicine to continue studies on the role of viruses and mutant cellular proteins in tumorigenic transformation of cells.
Yale’s Endocrine Neoplasia Program Is Flourishing
The Yale Multidisciplinary Endocrine Neoplasia Clinic has been treating benign and malignant diseases of the thyroid, parathyroid, adrenal, and pituitary glands since 2013. The program is a collaboration between the Department of Internal Medicine’s Section of Endocrinology & Metabolism and Yale Cancer Center and Smilow Cancer Hospital.
Doctors seeing success in HPV vaccine against cancers
(WTNH) – The only vaccine to prevent cancer has been on the market for a number of years, but doctors are now seeing the actual generation benefiting. It’s the HPV vaccine, which can prevent cervical cancer and it’s proving to be extremely effective. Doctor Elena Ratner, a gynecologic oncologist at Yale Cancer Center and Smilow Hospital says success is being seen as a result of Gardasil 9, the vaccine to prevent HPV, which is a sexually-transmitted disease that can lead to cancers.Source: WTNH
Yale expert familiar with procedure used on First Lady Jill Biden’s skin cancer
In light of First Lady Jill Biden's diagnosis and subsequent treatment for basal cell cancer, Yale dermatologic surgeons David Leffell, MD explains the symptoms of the condition and expands on the Moh's surgery technique used to remove the First Lady's cancer.Source: WTNH News8
Experts Study Implications of Genetic Markers in Prostate Cancer
In this video, Stacy Loeb, MD, MSc, and Veda N. Giri, MD, discuss the European Urology paper “Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention,” for which they served as coauthors. Giri is division chief of Clinical Cancer Genetics for Yale Cancer Center and Smilow Cancer and assistant director of Clinical Cancer Genetics for Yale Cancer Center, New Haven, Connecticut. Loeb is a professor in the departments of urology and population health at the NYU Grossman School of Medicine, New York City, New York.Source: Urology Times
HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact
Should breast cancer patients with low but not negative tumor expression of HER2 be considered a distinct patient group that can be treated differently from patients with tumors that are HER2 negative or HER2 positive? That was the question posed during a session at the recent San Antonio Breast Cancer Symposium (SABCS) 2022.Source: Medscape
The VA Launches Largest-Ever Trial on Screening Methods for Liver Cancer
The largest clinical trial in history related to liver cancer screening is launching in 2023, funded by the Department of Veterans Affairs. The project is scheduled to recruit 4,700 veterans with cirrhosis from 47 VA medical centers. Cirrhosis is a major risk factor for liver cancer and affects veterans disproportionally.
New Treatments Keeping Women Alive Longer Through Breast Cancer
Five percent of women diagnosed with breast cancer have metastatic disease, but survival rates are climbing. According to the Breast Cancer Research Foundation, the number of women living with metastatic breast cancer rose to 168,000 last year from 155,000 the year before. New breakthroughs keep women alive longer while researchers race to find the next therapy that will work.Source: WINK